Published in Clin Infect Dis on April 20, 2000
Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis (2008) 3.91
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun (2005) 3.13
Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis (2010) 2.86
Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med (2007) 2.85
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Efflux-mediated antifungal drug resistance. Clin Microbiol Rev (2009) 2.44
Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis (2010) 2.31
Chitosan, the deacetylated form of chitin, is necessary for cell wall integrity in Cryptococcus neoformans. Eukaryot Cell (2007) 1.76
Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother (2001) 1.70
Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol (2005) 1.61
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis (2009) 1.60
Combination treatment of invasive fungal infections. Clin Microbiol Rev (2005) 1.59
Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun (2007) 1.52
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol (2008) 1.51
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother (2008) 1.47
Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptococcus neoformans. Proc Natl Acad Sci U S A (2001) 1.44
Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One (2008) 1.43
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect Dis (2006) 1.43
Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother (2006) 1.40
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother (2008) 1.40
The pulmonary physician in critical care * Illustrative case 5: HIV associated pneumonia. Thorax (2003) 1.40
In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol (2004) 1.39
Role of a CUF1/CTR4 copper regulatory axis in the virulence of Cryptococcus neoformans. J Clin Invest (2007) 1.32
Cryptococcus gattii: An Emerging Cause of Fungal Disease in North America. Interdiscip Perspect Infect Dis (2009) 1.31
Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One (2012) 1.30
Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother (2005) 1.28
Detection of Cryptococcus neoformans DNA in tissue samples by nested and real-time PCR assays. Clin Diagn Lab Immunol (2002) 1.27
The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. J Acquir Immune Defic Syndr (2008) 1.26
Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev (2009) 1.21
In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother (2004) 1.21
Antifungal drug resistance of oral fungi. Odontology (2010) 1.21
Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis (2008) 1.20
Treatment of cryptococcal meningitis in resource limited settings. Curr Opin Infect Dis (2009) 1.18
Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis (2007) 1.16
First report of a case of meningitis caused by Cryptococcus adeliensis in a patient with acute myeloid leukemia. J Clin Microbiol (2004) 1.16
Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS One (2008) 1.14
The prevalence and clinical course of HIV-associated pulmonary cryptococcosis in Uganda. J Acquir Immune Defic Syndr (2010) 1.13
Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother (2006) 1.13
It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug. Front Microbiol (2012) 1.11
Retrospective analysis of 76 immunocompetent patients with primary pulmonary cryptococcosis. Lung (2012) 1.10
Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob Agents Chemother (2004) 1.10
Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother (2005) 1.09
Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS (2010) 1.07
Susceptibility of Cryptococcus neoformans to photodynamic inactivation is associated with cell wall integrity. Antimicrob Agents Chemother (2007) 1.05
Therapy of Cryptococcal Meningitis in non-HIV-infected Patients. Curr Infect Dis Rep (2001) 1.05
Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillus fumigatus isolates. Antimicrob Agents Chemother (2002) 1.04
Clinical presentation, diagnosis and management of Cryptococcus gattii cases: Lessons learned from British Columbia. Can J Infect Dis Med Microbiol (2009) 1.03
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob Agents Chemother (2006) 1.03
Not your "typical patient": cryptococcal meningitis in an immunocompetent patient. J Neurosci Nurs (2005) 1.02
In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother (2003) 1.01
In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol (2005) 0.98
Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice. Clin Vaccine Immunol (2011) 0.98
Fungal PDR transporters: Phylogeny, topology, motifs and function. Fungal Genet Biol (2009) 0.98
Disseminated cryptococcosis with meningitis, peritonitis, and cryptococcemia in a HIV-negative patient with cirrhosis: a case report. Cases J (2009) 0.98
Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment. Eur J Clin Microbiol Infect Dis (2013) 0.97
Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. Antimicrob Agents Chemother (2010) 0.97
Clinical analysis of 68 patients with pulmonary mycosis in China. Multidiscip Respir Med (2011) 0.97
Fungal infections in transplant and oncology patients. Infect Dis Clin North Am (2010) 0.96
Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo. Cell Microbiol (2010) 0.95
De novo GTP biosynthesis is critical for virulence of the fungal pathogen Cryptococcus neoformans. PLoS Pathog (2012) 0.94
Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans. Antimicrob Agents Chemother (2005) 0.93
Cell wall chitosan is necessary for virulence in the opportunistic pathogen Cryptococcus neoformans. Eukaryot Cell (2011) 0.92
Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens. Bioorg Med Chem (2010) 0.92
Cryptococcus infection in tropical Australia. J Clin Microbiol (2004) 0.92
Mortality associated with central nervous system tuberculosis. J Infect (2007) 0.90
Classical versus alternative macrophage activation: the Ying and the Yang in host defense against pulmonary fungal infections. Mucosal Immunol (2014) 0.90
First report of Cryptococcus albidus--induced disseminated cryptococcosis in a renal transplant recipient. Korean J Intern Med (2004) 0.89
A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins. Proteomics (2009) 0.89
Epidemiology of invasive fungal infections in the mediterranean area. Mediterr J Hematol Infect Dis (2011) 0.89
A proposed roadmap for inpatient neurology quality indicators. Neurohospitalist (2011) 0.89
Nonvalue of culturing cerebrospinal fluid for fungi. J Clin Microbiol (2004) 0.87
Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study. BMC Infect Dis (2005) 0.87
Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models. Front Microbiol (2012) 0.86
Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis. Antimicrob Agents Chemother (2013) 0.86
Evaluation of the NCCLS M44-P disk diffusion method for determining susceptibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazole. J Clin Microbiol (2004) 0.85
Management of cryptococcosis: how are we doing? PLoS Med (2007) 0.84
Chitinases are essential for sexual development but not vegetative growth in Cryptococcus neoformans. Eukaryot Cell (2009) 0.84
The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug. Antimicrob Agents Chemother (2014) 0.84
Cryptococcal meningitis in patients with or without human immunodeficiency virus: experience in a tertiary hospital. Yonsei Med J (2011) 0.84
Activity of tannins from Stryphnodendron adstringens on Cryptococcus neoformans: effects on growth, capsule size and pigmentation. Ann Clin Microbiol Antimicrob (2009) 0.84
A case of pulmonary cryptococcosis by capsule-deficient Cryptococcus neoformans. Korean J Intern Med (2006) 0.84
Treatment and outcomes among patients with Cryptococcus gattii infections in the United States Pacific Northwest. PLoS One (2014) 0.84
Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis (2014) 0.83
Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. Antimicrob Agents Chemother (2004) 0.83
Pneumonia and pregnancy. Thorax (2001) 0.83
Cryptococcal meningitis with acute psychotic confusion in a sarcoid patient. Prim Care Companion J Clin Psychiatry (2007) 0.82
Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii. Antimicrob Agents Chemother (2010) 0.82
Management of cryptococcal meningitis in HIV-infected patients: Experience from western India. Indian J Sex Transm Dis (2010) 0.82
Effects of immunomodulatory and organism-associated molecules on the permeability of an in vitro blood-brain barrier model to amphotericin B and fluconazole. Antimicrob Agents Chemother (2009) 0.81
In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob Agents Chemother (2005) 0.81
Late presentation of Cryptococcus gattii meningitis in a traveller to Vancouver Island: A case report. Can J Infect Dis Med Microbiol (2007) 0.81
Return of meningeal symptoms in a patient treated for cryptococcal meningitis. J Neurol (2007) 0.80
Cryptococcosis of lumbar vertebra in a patient with rheumatoid arthritis and scleroderma: case report and literature review. BMC Infect Dis (2013) 0.79
Cryptococcus and Phagocytes: Complex Interactions that Influence Disease Outcome. Front Microbiol (2016) 0.79
Proteogenomic analysis of pathogenic yeast Cryptococcus neoformans using high resolution mass spectrometry. Clin Proteomics (2014) 0.79
The prevalence, clinical features, risk factors and outcome associated with cryptococcal meningitis in HIV positive patients in Kenya. East Afr Med J (2010) 0.79
Fungal infections: their diagnosis and treatment in transplant recipients. Int J Hepatol (2012) 0.79
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med (1994) 9.11
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev (1995) 8.81
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev (1999) 5.84
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.73
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum (1981) 5.24
Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. J Bacteriol (1993) 5.14
Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother (1988) 4.79
Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol (1980) 4.28
Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med (1996) 4.28
Cryptococcus neoformans mating and virulence are regulated by the G-protein alpha subunit GPA1 and cAMP. Genes Dev (1997) 4.28
Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol (2000) 4.26
Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med (1991) 4.20
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet (2005) 4.17
Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature (1992) 4.11
Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis (2001) 4.01
Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis (1989) 4.01
Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest (1985) 3.98
Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med (1983) 3.97
Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol (1985) 3.97
Oral azole drugs as systemic antifungal therapy. N Engl J Med (1994) 3.96
Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother (1993) 3.79
Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med (1996) 3.76
Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages. J Clin Invest (1988) 3.69
Urease as a virulence factor in experimental cryptococcosis. Infect Immun (2000) 3.53
Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis (1996) 3.52
Computer surveillance of hospital-acquired infections and antibiotic use. JAMA (1986) 3.42
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother (1986) 3.38
Prosthetic valve endocarditis. Analysis of 38 cases. Circulation (1973) 3.29
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis (1990) 3.19
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother (1997) 3.17
Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans. Mol Cell Biol (2001) 3.11
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis (1998) 3.09
Critical role of germ tube formation in the pathogenesis of candidal vaginitis. Infect Immun (1984) 3.07
Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol (2001) 3.02
Development of a computerized infectious disease monitor (CIDM). Comput Biomed Res (1985) 2.93
Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J Clin Invest (1990) 2.91
Treatment of infective endocarditis: a 10-year comparative analysis. Circulation (1978) 2.90
Infection due to Actinobacillus actinomycetemcomitans: 15 cases and review. Rev Infect Dis (1989) 2.89
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother (1997) 2.76
Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med (1995) 2.63
Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis (1999) 2.57
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG (2011) 2.41
Pulmonary cryptococcosis in patients without HIV infection. Chest (1999) 2.31
Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol (1998) 2.30
RAS1 regulates filamentation, mating and growth at high temperature of Cryptococcus neoformans. Mol Microbiol (2000) 2.30
Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol (2005) 2.29
Adherence of Candida albicans to human vaginal and buccal epithelial cells. J Infect Dis (1981) 2.27
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med (1987) 2.20
Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis (2006) 2.17
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis (2000) 2.15
Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis (2001) 2.15
Nosocomial Pseudomonas cepacia infection associated with chlorhexidine contamination. Am J Med (1982) 2.14
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1999) 2.14
Comparison of restriction enzyme analysis and pulsed-field gradient gel electrophoresis as typing systems for Candida albicans. J Clin Microbiol (1991) 2.12
Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis (1995) 2.11
Cryptococcemia. Medicine (Baltimore) (1983) 2.10
Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis (2007) 2.09
Sex differences in nevirapine rash. Clin Infect Dis (2000) 2.09
Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clin Infect Dis (2000) 2.08
Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group. J Clin Microbiol (1996) 2.08
Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect Immun (1993) 2.08
Validity of the vaginal gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol (1996) 2.07
A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med (1991) 2.06
Macrophage-mediated fungistasis in vitro: requirements for intracellular and extracellular cytotoxicity. J Immunol (1986) 2.06
Alopecia associated with fluconazole therapy. Ann Intern Med (1995) 2.05
Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis (1999) 2.04
The G-protein beta subunit GPB1 is required for mating and haploid fruiting in Cryptococcus neoformans. Mol Cell Biol (2000) 2.03
Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci. JAMA (1989) 2.03
Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother (1985) 2.02
Identification of the MATa mating-type locus of Cryptococcus neoformans reveals a serotype A MATa strain thought to have been extinct. Proc Natl Acad Sci U S A (2000) 1.96
Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev (1996) 1.90
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
Risk factors for second urinary tract infection among college women. Am J Epidemiol (2000) 1.88
In vitro activity of LY127935, a new 1-oxa cephalosporin, against aerobic gram-negative bacilli. Antimicrob Agents Chemother (1979) 1.87
Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J Infect Dis (1987) 1.85
Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect Immun (1993) 1.84
Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis (1993) 1.81
Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med (1986) 1.81
Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis (2000) 1.80
Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. Antimicrob Agents Chemother (1985) 1.78